ImmunityBio, Inc.
IBRX
Jodie situation report
ImmunityBio, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
- Management says continuing operating cash outflows create substantial doubt about going concern without additional funding or financial support.
Invalidation: The isolated read changes if IBRX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind IBRX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
URGNUroGen Pharma Ltd.competitorMar 2, 2026 ▾
“We are aware of several pharmaceutical companies that are developing drugs in the general fields of urology and uro-oncology, such as AstraZeneca, Aura Biosciences., Bristol Myers Squibb, CG Oncology, enGene Holdings, Ferring Pharmaceuticals, Fidia Pharmaceut…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
IBRX is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.